Ablation
Covidien launches Halo60 ablation system for treatment of Barrett’s esophagus
Covidien (NYSE:COV) hailed the launch of its Halo60 ablation catheter, the latest addition to its portfolio of catheters for treating Barrett’s esophagus.
Barrett’s esophagus is a precancerous condition in the lining of the windpipe, which can lead to chronic injury and inflammation from the backward flow of stomach contents.
CardioFocus launches pivotal trial for HeartLight ablation system
CardioFocus successfully treated the first patient in a pivotal trial of its HeartLight endoscopic ablation system for atrial fibrillation.
The HeartLight device is the first of its kind to to allow direct visualization of a beating heart in real time, without using radiation, to allow physicians to better aim delivery of ablation energy, according to a press release.
St. Jude lands FDA win for 2 next-gen cardiac ablation catheters | Regulatory Roundup
St. Jude Medical Inc. (NYSE:STJ) won pre-market approval for 2 next-generation cardiac ablation systems this month, the Therapy Cool Path Duo and Safire Blu Duo catheters.
Both ablation systems use radiofrequency energy to freeze small areas of faulty cardiac tissue in patients with typical trial flutter, a type of arrhythmia in which patients experience abnormal heart rhythms or an abnormally fast heartbeat in the upper chambers of the heart.
Stents: Drug-eluters beat bare metal for patients over 85
Drug-eluting stents dealt another blow to their bare-metal cousins by leading to fewer adverse events post-procedure in patients over the age of 85 undergoing percutaneous coronary intervention, new research shows.
Patient with drug-eluting stents showed a 29% mortailty risk, compared with a 38% risk in patients with bare-metal stents, with the difference narrowing with increasing age, according to the study, published in the Journal of the American College of Cardiology.
FDA approves AtriCure’s Synergy cardiac ablation device | Regulatory Roundup
AtriCure (NSDQ:ATRC) shares got a modest bump today after revealing pre-market approval from the FDA for its Synergy radiofrequency ablation system for atrial fibrillation.
ATRC shares were up 2.1% to $10.86 as of about 1 p.m. today.
FDA approves AtriCure’s Synergy cardiac ablation device
AtriCure (NSDQ:ATRC) shares got a modest bump today after revealing pre-market approval from the FDA for its Synergy radiofrequency ablation system for atrial fibrillation.
ATRC shares were up 2.1% to $10.86 as of about 1 p.m. today.
MassDevice.com +3 | CMS targets “unnecessary” med-tech, J&J withdraws appeal and re-opens PMA, Q&A with JoeDeVivo
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.